search
Back to results

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors

Primary Purpose

Advanced Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
RO7589831
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumors focused on measuring Deficient mismatch repair, dMMR, Microsatellite instability, MSI

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Have a locally confirmed microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor Have received and then progressed following or are intolerant to at least 1 standard treatment regimen in the advanced setting Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Life expectancy of at least (≥)12 weeks Availability of formaldehyde-fixed paraffin-embedded (FFPE) archival tumor tissue for submission to Sponsor/central laboratory for retrospective central testing; for participants without archival tissue, a biopsy from either primary or metastatic tumor lesion, deemed medically feasible, must be taken Adequate hematologic, end-organ, and cardiovascular function, as defined in the protocol Exclusion Criteria: Inability or unwillingness to swallow pills Malabsorption syndrome or other condition that would interfere with enteral absorption Known hypersensitivity or intolerance to ingredients from the study drug formulation including patients with rare genetic disorders such as galactosaemia, glucose-galactose intolerance or congenital lactase deficiency Known uncontrolled central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) and/or carcinomatous meningitis Known active or uncontrolled bacterial, viral, fungal, mycobacterial (including but not limited to tuberculosis and atypical mycobacterial disease), parasitic, or other infection (excluding fungal infections of nail beds), or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 2 weeks prior to the start of drug administration (related to the completion of the course of antibiotics, except if for tumor fever) or 6 months for any intracranial abscess Has a positive test at screening for hepatitis B virus, hepatitis C virus, or for human immodeficiency virus (HIV), per local diagnostic standard and in accordance with local laws and regulations Uncontrolled diabetes or symptomatic hyperglycemia (i.e., well controlled defined as a screening hemoglobin A1c <8% and no urinary ketoacidosis) Alcohol or drug dependence or abuse Patients with known Werner (WRN) syndrome Prior treatment with any WRN helicase inhibitor Pregnancy, breastfeeding, or intention of becoming pregnant during the study

Sites / Locations

  • City of HopeRecruiting
  • City of Hope at Irvine LennarRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Part I: RO7589831 Dose Escalation

Part II: RO7589831 Dose Expansion

Arm Description

Outcomes

Primary Outcome Measures

Incidence of Adverse Events, with Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)
Incidence of Dose-Limiting Toxicities

Secondary Outcome Measures

Maximum Plasma Concentration Observed (Cmax) of RO7589831
Time of Maximum Plasma Concentration Observed (Tmax) of RO7589831
Area Under the Plasma Concentration-Time Curve (AUC) of RO7589831
Apparent Oral Clearance (CL/F) of RO7589831
Volume of Distribution (V/F) of RO7589831
Terminal Half-Life (T1/2) of RO7589831
Objective Response Rate
Disease Control Rate
Duration of Response
Progression-Free Survival, as Assessed by the Investigator
Overall Survival

Full Information

First Posted
August 16, 2023
Last Updated
September 28, 2023
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT06004245
Brief Title
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors
Official Title
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 15, 2023 (Anticipated)
Primary Completion Date
December 22, 2025 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7589831 monotherapy in participants with MSI and/or dMMR advanced solid tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumors
Keywords
Deficient mismatch repair, dMMR, Microsatellite instability, MSI

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
This is an open label study. Participants will be assigned to dose cohorts in the order in which they are enrolled. However, if two or more cohorts in the same part of the study are open for enrollment at the same time, participants will be randomized into these cohorts.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
220 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part I: RO7589831 Dose Escalation
Arm Type
Experimental
Arm Title
Part II: RO7589831 Dose Expansion
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
RO7589831
Intervention Description
RO7589831 will be administered orally and once daily (QD) in 3-week cycles.
Primary Outcome Measure Information:
Title
Incidence of Adverse Events, with Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)
Time Frame
From first dose of study drug until 30 days after last dose of study drug (up to approximately 15 months)
Title
Incidence of Dose-Limiting Toxicities
Time Frame
Cycle 1 (1 cycle is 3 weeks)
Secondary Outcome Measure Information:
Title
Maximum Plasma Concentration Observed (Cmax) of RO7589831
Time Frame
At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Title
Time of Maximum Plasma Concentration Observed (Tmax) of RO7589831
Time Frame
At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Title
Area Under the Plasma Concentration-Time Curve (AUC) of RO7589831
Time Frame
At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Title
Apparent Oral Clearance (CL/F) of RO7589831
Time Frame
At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Title
Volume of Distribution (V/F) of RO7589831
Time Frame
At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Title
Terminal Half-Life (T1/2) of RO7589831
Time Frame
At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Title
Objective Response Rate
Time Frame
From start of study treatment until end of follow-up (up to approximately 36 months)
Title
Disease Control Rate
Time Frame
From start of study treatment until end of follow-up (up to approximately 36 months)
Title
Duration of Response
Time Frame
From the time of first occurrence of a documented response until the time of documented disease progression or death from any cause, whichever occurs first (up to approximately 36 months)
Title
Progression-Free Survival, as Assessed by the Investigator
Time Frame
From start of study treatment to the first occurrence of documented disease progression or death from any cause, whichever occurs first (up to approximately 36 months)
Title
Overall Survival
Time Frame
From start of study treatment to the time of death from any cause (up to approximately 36 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Have a locally confirmed microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor Have received and then progressed following or are intolerant to at least 1 standard treatment regimen in the advanced setting Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Life expectancy of at least (≥)12 weeks Availability of formaldehyde-fixed paraffin-embedded (FFPE) archival tumor tissue for submission to Sponsor/central laboratory for retrospective central testing; for participants without archival tissue, a biopsy from either primary or metastatic tumor lesion, deemed medically feasible, must be taken Adequate hematologic, end-organ, and cardiovascular function, as defined in the protocol Exclusion Criteria: Inability or unwillingness to swallow pills Malabsorption syndrome or other condition that would interfere with enteral absorption Known hypersensitivity or intolerance to ingredients from the study drug formulation including patients with rare genetic disorders such as galactosaemia, glucose-galactose intolerance or congenital lactase deficiency Known uncontrolled central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) and/or carcinomatous meningitis Known active or uncontrolled bacterial, viral, fungal, mycobacterial (including but not limited to tuberculosis and atypical mycobacterial disease), parasitic, or other infection (excluding fungal infections of nail beds), or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 2 weeks prior to the start of drug administration (related to the completion of the course of antibiotics, except if for tumor fever) or 6 months for any intracranial abscess Has a positive test at screening for hepatitis B virus, hepatitis C virus, or for human immodeficiency virus (HIV), per local diagnostic standard and in accordance with local laws and regulations Uncontrolled diabetes or symptomatic hyperglycemia (i.e., well controlled defined as a screening hemoglobin A1c <8% and no urinary ketoacidosis) Alcohol or drug dependence or abuse Patients with known Werner (WRN) syndrome Prior treatment with any WRN helicase inhibitor Pregnancy, breastfeeding, or intention of becoming pregnant during the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reference Study ID Number: BP44474 https://forpatients.roche.com/
Phone
888-662-6728 (U.S. Only)
Email
global-roche-genentech-trials@gene.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
City of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Name
City of Hope at Irvine Lennar
City
Irvine
State/Province
California
ZIP/Postal Code
92618
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
For eligible studies, qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). Roche's Global Policy on the Sharing of Clinical Information describes studies which are eligible for data sharing and how to request access (https://www.roche.com/innovation/process/clinical-trials/data-sharing/).

Learn more about this trial

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors

We'll reach out to this number within 24 hrs